Hualead Pharmaceuticals-B (02552): Termination of Bayer Hofmann's agency sales rights from January 1, 2025.

Hua Ling Medicine-B (02552) announced that the company has sent a written notice to Bayer Healthcare LLC, indicating its intention to transfer the commercialization responsibility of the innovative glucose kinase activator, Huatangning, developed for the treatment of type 2 diabetes in china, to the company starting from January 1, 2025.

Zhitong FinanceNov 21 21:05 ET

Hua Ling Pharmaceutical (02552) to regain commercialization rights of Hua Tangning from Bayer Pharmaceutical Company in China.

Gold Summit Financial News | Hualing Medicine (02552) announced that on November 21, 2024, its wholly-owned subsidiary Hualing shanghai issued a written notice to Bayer Healthcare Co., Ltd., indicating the intention to transition the commercialization responsibility of the company's original glucose kinase activator Huatingning (dorzagliatin tablets) for the treatment of type 2 diabetes in china to the company starting from January 1, 2025. On August 17, 2020, the parties involved established a cooperative relationship for the commercialization of Huatingning in china and signed a related exclusive promotion service agreement. According to the agreement, Bayer obtained the rights to Huatingning in china.

Golden Guardian Financial NewsNov 21 19:53 ET

Hua Medicine Terminates Commercialization Agreement With Bayer for Type 2 Diabetes Treatment

MT NewswiresNov 21 19:47 ET

Hua Ling Pharmaceuticals-B (02552.HK) announced the commercial transition of Huatangning, opening up a new market strategy.

Gelonghui November 22nd | Huali Pharma-B (02552.HK) announced that on November 21, 2024, its wholly-owned subsidiary Huali Pharma Technology (Shanghai) Co., Ltd. ("Huali Shanghai") issued a written notice to Bayer Healthcare Co., Ltd. ("Bayer"), expressing its intention to transition the commercialization responsibility of the company's first-in-class glucose kinase activator dorzagliatin tablets for the treatment of type 2 diabetes in China to the company from January 1, 2025. On August 17, 2020, the relevant parties established the commercialization of dorzagliatin in China.

Gelonghui FinanceNov 21 18:40 ET

HUA MEDICINE-B: INTERIM REPORT 2024

HKEXSep 26 04:37 ET · Announcements

A visual guide to understanding the 2024 interim report of Hualing Pharmaceuticals-B (02552.HK)

On August 29, Hualing Pharmaceuticals-B(02552.HK) released its 2024 interim report. The following infographic will help you understand it.

Gelonghui FinanceAug 30 03:04 ET